Navigation Links
Spurred by food allergies, 2 esophagus conditions stump doctors
Date:12/16/2013

CHAPEL HILL, N.C. Researchers at the UNC School of Medicine found that two on-the-rise esophagus conditions are so similar that even a biopsy is not enough to distinguish one disease from the other.

One condition is called eosinophilic esophagitis, or EoE. The other is PPI-responsive esophageal eosinophilia, or PPI-REE. Symptoms for each condition include difficulty swallowing, persistent heartburn, and getting food stuck in the throat. Both are diagnosed with an endoscopy, which reveals high numbers of a certain type of white blood cell an eosinophil in biopsies of both conditions. But finding a lot of white blood cells does not distinguish EoE from PPI-REE, said Evan Dellon, MD, MPH, associate professor of medicine and epidemiology and lead author of a study published in the American Journal of Gastroenterology.

Dellon says that both conditions can be the result of a food allergy, but they require different treatments.

Patients whose white blood cell count can be lowered by antacid medications, also called proton-pump inhibitor (PPI) medications, are diagnosed with PPI-REE. However, finding out if the white blood cell count was lowered requires a second endoscopy and biopsy. If the count remained high, then patients are diagnosed with EoE and require an anti-inflammatory medication, such as a steroid typically used to treat asthma.

"Unfortunately, right now the only way to differentiate between the conditions is to do the PPI medication trial and then repeat the endoscopy," Dellon said.

During his study, Dellon's team wanted to see if any symptoms, endoscopic views of the esophagus, or tissue samples could help him differentiate the two conditions so that future patients wouldn't have to go through an eight-week antacid trial and a second endoscopic biopsy, an invasive procedure that is safe but costly and requires sedation.

The study enrolled 223 patients with esophageal complaints. Dellon's team took small samples of tissue from the patients and examined them for the presence of eosinophilswhite blood cells. Patients with a high eosinophil count were given an 8-week course of antacids. The study showed that approximately 30 to 40 percent of the participants responded to the antacid medication. They were diagnosed with PPI-REE.

Patients who did not respond to antacids were diagnosed with EoE. There are no FDA-approved medicines for EoE, so the steroids that doctors prescribe are considered off-label use. There are, however, several randomized, double-blind studies that show that these medications work for EoE.

"The other option for treating EoE is to try a variety of elimination diets to remove the most common food triggers, such as wheat, dairy, soy, or eggs," Dellon said. "We know that it's mostly an allergic reaction because if you take away all allergens, nearly everyone will get better very quickly. But that isn't a practical treatment for many people."

After rigorous analysis, Dellon and his colleagues did not find any clinical or endoscopic characteristics that could reliably distinguish the two conditions. This means patients will still need to undergo the PPI trial and repeat endoscopy in order to be properly diagnosed.

Dellon's team is working on an extension of this study that uses a special stain on the cell biopsies that he hopes will predict who will respond to antacids. Dellon also wants to investigate patient genetics as a possible diagnostic tool.

"This whole antacid response and even the existence of PPI-REE as a condition weren't really described well until two years ago," Dellon said. "So the diagnostics are still very much in flux right now."


'/>"/>

Contact: Mark Derewicz
mark.derewicz@unch.unc.edu
919-923-0959
University of North Carolina Health Care
Source:Eurekalert  

Related biology news :

1. Researchers find first evidence for a genetic cause for Barretts oesophagus
2. Shadehouses with photoselective nets featured in study of growing conditions
3. Redwood trees reveal history of West Coast rain, fog, ocean conditions
4. Researchers quantify toxic ocean conditions during major extinction 93.9 million years ago
5. South African living stone plant adapts to extreme conditions in new ways
6. CWRU makes nanodiamonds in ambient conditions
7. Biofilms help Salmonella survive hostile conditions, Virginia Tech researchers say
8. New study finds neither HFCS nor table sugar increases liver fat under real world conditions
9. UCI study reveals why Down syndrome boosts susceptibility to other conditions
10. Under the right conditions, peptide blocks HIV infection at multiple points along the way
11. Better housing conditions for zebrafish could improve research results
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Spurred by food allergies, 2 esophagus conditions stump doctors
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
Breaking Biology News(10 mins):
(Date:6/28/2017)... , ... June 28, 2017 , ... Supplies of the ... leading experts gathered at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2017 ... technetium-99m (Tc-99m), which is used in 30 to 40 million nuclear medicine procedures worldwide ...
(Date:6/27/2017)... , ... June 27, 2017 , ... Biodex Medical Systems, ... ambulation aid in one device. This assistive aid lifts patients safely from a seated ... and motorized lift mechanics. The Mobility Assist is the latest in a line of ...
(Date:6/26/2017)... , ... June 26, 2017 , ... ... Melissa Kirkegaard, the former Associate Director of Product Development R&D at Allergan and ... pharmaceutical products at both start-up and established biopharma companies, has joined the firm ...
(Date:6/23/2017)... IA (PRWEB) , ... June 23, 2017 , ... Biova, ... Henig, Ph.D. has joined Biova’s Board of Directors. Dr. Henig will bring a wealth ... Dr. Henig has served as the Chief Technical and Scientific Officer of four major ...
Breaking Biology Technology: